Drugs:孟鲁司特治疗变应性鼻炎的疗效:系统综述和荟萃分析

2020-09-28 AlexYang MedSci原创

在治疗变应性鼻炎时,孟鲁司特有可能作为口服抗组胺剂或鼻内皮质类固醇的替代品或添加剂使用。本系统综述评估了孟鲁司特治疗变应性鼻炎的有效性。

在治疗变应性鼻炎时,孟鲁司特有可能作为口服抗组胺剂或鼻内皮质类固醇的替代品或添加剂使用。本系统综述评估了孟鲁司特治疗变应性鼻炎的有效性。

研究人员使用Cochrane中心从1966年到2019年1月21日登记的对照试验、EMBASE和MEDLINE进行电子文献检索。入选标准是比较孟鲁司特与安慰剂或其他标准治疗的随机对照试验。主要评估结果为日间鼻部症状评分(DNS)和夜间鼻部症状评分(NNS)。次要评估结果为综合鼻症状评分(CSS)、日间眼睛症状评分(DES)和鼻结膜炎生活质量问卷(RQLQ)。他们采用基于随机效应模型的Review Manager 5.3软件进行meta分析。

15项研究的10387名参与者符合纳入标准。结果显示,孟鲁司特改善DNS(平均差异[MD] - 0.12, 95%置信区间[CI] - 0.15 ~ - 0.08;p < 0.001)、NNS (MD - 0.09, 95% CI - 0.13 ~ - 0.05;p < 0.001)、CSS (MD - 0.08, 95% CI - 0.11 ~ - 0.06;p < 0.001)、DES (MD - 0.17, 95% CI - 0.33 ~ - 0.02;p < 0.030)和RQLQ (MD - 0.34, 95% CI - 0.49 ~ - 0.20;p < 0.001)的效果均优于安慰剂。口服抗组胺剂(OAH)改善DNS(MD 0.08, 95% CI 0.03-0.13;p = 0.002)、 CSS (MD 0.03, 95% CI - 0.02 ~ 0.07;p = 0.27)、DES (MD 0.06, 95% CI 0-0.12;p = 0.040),和RQLQ (MD 0.03, 95% CI - 0.05 ~ 0.12;p = 0.430)的效果优于孟鲁司特。孟鲁司特对NNS(MD -0.03, 95% CI - 0.08 ~ 0.03;p = 0.330)的改善优于口服抗组胺剂。氟替卡松鼻喷剂对DNS(MD 0.71, 95% CI 0.44-0.99;p < 0.001)和NNS (MD 0.63, 95% CI 0.29-0.97;p < 0.001)的改善效果优于孟鲁司特。孟鲁司特联合口服抗组胺剂改善DNS(MD - 0.15, 95% CI - 0.27 ~ - 0.03; p = 0.010)、NNS (MD - 0.16, 95% CI - 0.28 ~ - 0.05;p = 0.006)、CSS (MD - 0.12, 95% CI - 0.25~- 0.01;p = 0.070、DES (MD - 0.12, 95% CI - 0.30 - 0.06;;p = 0.180)和RQLQ (MD - 0.10, 95% CI - 0.28 - 0.08;p = 0.290)的效果优于口服抗组胺剂。孟鲁司特联合OAH改善DNS(MD 0.15, 95% CI 0.08-0.21; p < 0.001)、NNS (MD 0.05, 95% CI - 0.09 ~ 0.19;p = 0.510)、CSS (MD 0.1, 95% CI 0.03-0.17;p = 0.007)、 DES (MD 0.18, 95% CI 0-0.36;p = 0.050)和RQLQ (MD 0.07 95% CI - 0.15 ~ 0.29;p = 0.530)的效果优于孟鲁司特。

孟鲁司特与孟鲁司特联用口服抗组胺药发现总结

该研究表明,对于变应性鼻炎的整体症状,孟鲁司特比安慰剂更有效,而孟鲁司特与口服抗组胺药联合治疗优于单独口服抗组胺药或孟鲁司特联合治疗。

原始出处:

Krishnamoorthy M, Mohd Noor N, Mat Lazim N, Abdullah B. Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis. Drugs. 2020 Sep 11

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-11-08 wangbingxhy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-05-30 tsing_hit
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-05-07 venlin
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1862348, encodeId=7b8f186234815, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Sun Nov 08 14:34:31 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784776, encodeId=25f41e8477601, content=<a href='/topic/show?id=e451626993' target=_blank style='color:#2F92EE;'>#drugs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6269, encryptionId=e451626993, topicName=drugs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 30 07:34:31 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971852, encodeId=6e3919e185280, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Apr 12 15:34:31 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681392, encodeId=918d168139258, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Fri May 07 08:34:31 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836952, encodeId=044c1836952fd, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat May 01 07:34:31 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928524, encodeId=eaea19285249a, content=<a href='/topic/show?id=b6054539596' target=_blank style='color:#2F92EE;'>#孟鲁司特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45395, encryptionId=b6054539596, topicName=孟鲁司特)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Wed Jul 07 02:34:31 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323324, encodeId=f34b132332422, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Wed Sep 30 13:34:31 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032659, encodeId=7262103265946, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 29 01:34:31 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-09-29 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

JAMA Oncol:骨髓瘤维持治疗,哪个方案更优?

目前已有多项研究探索了多发性骨髓瘤(MM)的维持治疗。尽管研究结果提示维持治有一定疗效,但尚无证据显示何种维持治疗方案更优。近期,发布于JAMA Oncology杂志的一项荟萃分析,探讨了各个维持治疗方案对比无维持治疗或安慰剂维持的疗效,并在特定人群中进行了疗效对比。

Semin Arthritis Rheu:他汀类药物对类风湿性关节炎风险的影响

在这项系统回顾和荟萃分析中,观察到他汀类药物使用者与非使用者的RA风险无差异。

Semin Arthritis Rheu:室外空气污染与患类风湿性关节炎风险的关联

现有证据表明,空气污染的某些指标(臭氧、靠近公路和PM2.5)与RA之间存在显著关联。

Pancreas:他汀类药物对胰腺癌或有保护作用

在线发表于《Pancreas》杂志上的一项针对26项研究的荟萃分析显示,使用他汀类药物可显著降低胰腺癌风险,该结果支持了他汀类药物对胰腺癌有保护作用的假设。

Lancet Respir Med:耐多药结核病治疗过程中不良事件的发生

耐多药结核病的治疗需要长期治疗,且需要多种二线药物的联合治疗。这些药物与许多不良事件的发生相关,而这些不良事件可能导致诸如耳聋等严重疾病的发生,且在某些情况下可能会导致患者死亡。本研究旨在评估与不同结